Global Genetic disorders Partnering 2010-2016: Deal trends, players and financials

Published: November 2016
No. of Pages: 500
    ReportsandReports

“Delivery of this report will take 1-3 days after purchase.”

Global Genetic Disorders Partnering 2010 to 2016 provides the full collection of Genetic Disorders disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.

Trends in Genetic Disorders partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Genetic Disorders partnering agreement structure
Genetic Disorders partnering contract documents
Top Genetic Disorders deals by value
Most active Genetic Disorders dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genetic Disorders dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genetic Disorders dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genetic Disorders deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Genetic Disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genetic Disorders deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genetic Disorders partnering deals by specific Genetic Disorders target announced since 2010. The chapter is organized by specific Genetic Disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genetic Disorders partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genetic Disorders partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genetic Disorders technologies and products.

Report scope

Global Genetic Disorders Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Genetic Disorders trends and structure of deals entered into by leading companies worldwide.

Global Genetic Disorders Partnering 2010 to 2016 includes:

Trends in Genetic Disorders dealmaking in the biopharma industry since 2010
Analysis of Genetic Disorders deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Genetic Disorders deal contract documents
Comprehensive access to over 3500 Genetic Disorders deal records
The leading Genetic Disorders deals by value since 2010
Most active Genetic Disorders dealmakers since 2010

The report includes deals for the following indications: Cystic Fibrosis (CF), Down syndrome, Fragile X Syndrome, Hereditary angioedema, Huntington's disease, Rare genetic disorders, Neurofibromatosis, Sickle cell disease, plus other genetic indications.

In Global Genetic Disorders Partnering 2010 to 2016, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Genetic Disorders Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 400 genetic disorders deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Global Genetic Disorders Partnering 2010 to 2016 provides the reader with the following key benefits:

In-depth understanding of Genetic Disorders deal trends since 2010
Access Genetic Disorders deal headline, upfront, milestone and royalty data
Research hundreds of actual contracts between Genetic Disorders partner companies
Comprehensive access to over 750 links to actual Genetic Disorders deals entered into by the world’s biopharma companies
Indepth review of Genetic Disorders deals entered into by the top 25 most active dealmakers
Benchmark the key deal terms companies have agreed in previous deals
Identify key terms under which companies partner Genetic Disorders opportunities
Uncover companies actively partnering Genetic Disorders opportunities

Published By: Current Partnering
Product Code: Current Partnering548


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:

  • United States SSRI Market Report 2016

    Notes: Sales, means the sales volume of SSRI Revenue, means the sales value of SSRI This report studies sales (consumption) of SSRI in United States market, focuses on the top players, with sales, price, revenue and market share for each player,...

  • Global SSRI Sales Market Report 2016

    Notes: Sales, means the sales volume of SSRI Revenue, means the sales value of SSRI This report studies sales (consumption) of SSRI in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/coun...

  • United States Eyedrops Market Report 2016

    Notes: Sales, means the sales volume of Eyedrops Revenue, means the sales value of Eyedrops This report studies sales (consumption) of Eyedrops in United States market, focuses on the top players, with sales, price, revenue and market share for ...

  • Japan Eyedrops Market Report 2016

    Notes: Sales, means the sales volume of Eyedrops Revenue, means the sales value of Eyedrops This report studies sales (consumption) of Eyedrops in Japan market, focuses on the top players, with sales, price, revenue and market share for each pla...

  • Europe Eyedrops Market Report 2016

    Notes: Sales, means the sales volume of Eyedrops Revenue, means the sales value of Eyedrops This report studies sales (consumption) of Eyedrops in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top...

  • China Eyedrops Market Research Report 2016

    Notes: Sales, means the sales volume of Eyedrops Revenue, means the sales value of Eyedrops This report studies Eyedrops in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for ...

  • Global Eyedrops Sales Market Report 2016

    Notes: Sales, means the sales volume of Eyedrops Revenue, means the sales value of Eyedrops This report studies sales (consumption) of Eyedrops in Global market, especially in United States, China, Europe, Japan, focuses on top players in these ...

  • Europe Myeloproliferative Disorders Clinical Trials Market Report 2016

    Notes: Sales, means the sales volume of Myeloproliferative Disorders Clinical Trials Revenue, means the sales value of Myeloproliferative Disorders Clinical Trials This report studies sales (consumption) of Myeloproliferative Disorders Clinical ...

  • United States Tramadol Market Report 2016

    Notes: Sales, means the sales volume of Tramadol Revenue, means the sales value of Tramadol This report studies sales (consumption) of Tramadol in United States market, focuses on the top players, with sales, price, revenue and market share for ...

  • United States Meloxicam Market Report 2016

    Notes: Sales, means the sales volume of Meloxicam Revenue, means the sales value of Meloxicam This report studies sales (consumption) of Meloxicam in United States market, focuses on the top players, with sales, price, revenue and market share f...


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: